KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables (2016 - 2025)

Historic Receivables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $524.4 million.

  • Sarepta Therapeutics' Receivables rose 469.43% to $524.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $524.4 million, marking a year-over-year increase of 469.43%. This contributed to the annual value of $636.6 million for FY2024, which is 4800.28% up from last year.
  • Sarepta Therapeutics' Receivables amounted to $524.4 million in Q3 2025, which was up 469.43% from $600.6 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Receivables peaked at $714.6 million during Q1 2025, and registered a low of $133.3 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $285.8 million (2023), whereas its average is $346.3 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Receivables surged by 9736.12% in 2023, and later surged by 469.43% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Receivables (Quarter) stood at $153.0 million in 2021, then skyrocketed by 42.44% to $217.9 million in 2022, then soared by 97.36% to $430.1 million in 2023, then surged by 48.0% to $636.6 million in 2024, then dropped by 17.62% to $524.4 million in 2025.
  • Its Receivables stands at $524.4 million for Q3 2025, versus $600.6 million for Q2 2025 and $714.6 million for Q1 2025.